BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-675@pharmaconomics
DTSTAMP:20260707T050712Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:DNLI Approval — AVLAYAH™
DESCRIPTION:A final FDA approval decision on AVLAYAH™ for Hunter syndrome (MPS II) is expected Mar 25\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm\n\nTrack it: https://www.pharmaconomics.com/e/675
URL:https://www.pharmaconomics.com/e/675
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR